These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26199172)

  • 41. [Correlation between detrusor thickness, intravesical prostatic protrusion and maximum urinary flow in the monitoring of benign prostatic hyperplasia].
    Boulma R; Charfi M; Trigui M; Daoud MF; Sahnoun M; Bouhaouala MH; Chouchen A
    Prog Urol; 2022 Mar; 32(4):291-297. PubMed ID: 34801388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ultrasound indicators of the prostate, urinary bladder and uroflowmetry parameters in the diagnosis of infravesical obstruction in men with benign prostatic hyperplasia].
    Krivoborodov GG; Efremov NS; Bolotov AD
    Urologiia; 2017 Oct; (5):9-14. PubMed ID: 29135135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
    Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultrasound assessment of intravesical prostatic protrusion and detrusor wall thickness--new standards for noninvasive bladder outlet obstruction diagnosis?
    Franco G; De Nunzio C; Leonardo C; Tubaro A; Ciccariello M; De Dominicis C; Miano L; Laurenti C
    J Urol; 2010 Jun; 183(6):2270-4. PubMed ID: 20400138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH).
    Elshal AM; Elmansy HM; Elhilali MM
    BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up?
    Rigatti L; Naspro R; Salonia A; Centemero A; Ghezzi M; Guazzoni G; Briganti A; Rigatti P; Montorsi F
    Urology; 2006 Jun; 67(6):1193-8. PubMed ID: 16750253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Effect of Intravesical Prostatic Protrusion in Patients with Benign Prostatic Hyperplasia: Controlled, Clinical Study.
    Kadihasanoglu M; Aydin M; Taskiran M; Kendirci M
    Urol Int; 2019; 103(2):180-186. PubMed ID: 31039569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Correlation of intravesical prostatic protrusion with clinical evaluation parameters in BPH patients].
    Han WK; Shan GZ; Jin J
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):254-7. PubMed ID: 20369556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction.
    Luo GC; Foo KT; Kuo T; Tan G
    Singapore Med J; 2013 Sep; 54(9):482-6. PubMed ID: 24068054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravesical Prostatic Protrusion: A Potential Marker of Alpha-blocker Treatment Success in Patients With Benign Prostatic Enlargement.
    Kalkanli A; Tandogdu Z; Aydin M; Karaca AS; Hazar AI; Balci MB; Aydin M; Nuhoglu B
    Urology; 2016 Feb; 88():161-5. PubMed ID: 26680245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sonographic Parameters Predicting the Outcome of Patients With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treated With Alpha1-Adrenoreceptor Antagonist.
    Ahmed AF
    Urology; 2016 Feb; 88():143-8. PubMed ID: 26607685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
    Mariappan P; Brown DJ; McNeill AS
    J Urol; 2007 Aug; 178(2):573-7; discussion 577. PubMed ID: 17570437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Noninvasive assessment of prostatic obstruction in elderly men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    van Venrooij GE; Eckhardt MD; Boon TA
    Urology; 2004 Mar; 63(3):476-80. PubMed ID: 15028441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
    Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
    Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
    Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prostatic middle lobe: clinical significance, presentation and management.
    Gharbieh S; Reeves F; Challacombe B
    Nat Rev Urol; 2023 Nov; 20(11):645-653. PubMed ID: 37188789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prostatic middle lobe hyperplasia correlates with bladder outflow obstruction: analysis of 131 cases].
    Shen H; Zhou HT; Wu HF; Yu HB; Li BJ; Zhang B; Lin JZ
    Zhonghua Nan Ke Xue; 2011 Jun; 17(6):527-30. PubMed ID: 21735652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.